H. Stewart Parker Joins Impel NeuroPharma's Board of Directors

H. Stewart Parker Joins Impel NeuroPharma's Board of Directors

Impel NeuroPharma is pleased to announce that H. Stewart Parker, a prominent leader in Seattle's Biotechnology community, has joined Impel's Board of Directors.

Most recently, Parker was the CEO of the Seattle-based Infection Disease Research Institute (IDRI), a nonprofit global health research institute developing diagnostics, vaccines, and treatments for neglected diseases. Parker started her career in biotech as the first employee of Immunex, growing with the company to become Vice President of Corporate Development.
 

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.